Diagnosis of Breast Carcinoma with Radiolabeled Monoclonal Antibodies (MoAbs) to Carcinoembryonic Antigen (CEA) and Human Milk Fat Globulin (HMFG)

The current study attempted to assess the potential proficiency of radioimmunodetection (RAID) of primary, residual, multicentric, and recurrent breast carcinoma using two radiolabeled murine monoclonal antibodies (MoAbs), anti-human milk fat globulin (HMFG1) labeled with iodine (123I) and anti-carc...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer investigation Ročník 13; číslo 6; s. 573 - 582
Hlavní autoři: Rosner, Dutzu, Nabi, Hani, Wild, Linda, Ortman-Nabi, Judith, Hreshchyshyn, Myroslaw M.
Médium: Journal Article
Jazyk:angličtina
Vydáno: New York, NY Informa UK Ltd 1995
Taylor & Francis
Informa Healthcare
Témata:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal - metabolism
Biological and medical sciences
Breast Neoplasms - diagnostic imaging
Breast Neoplasms - metabolism
Carcinoembryonic Antigen - immunology
Endocrine glands. Genital system. Mammary gland
Fats - immunology
Female
Humans
Immunohistochemistry
Investigative techniques, diagnostic techniques (general aspects)
Iodine Radioisotopes
Lactoglobulins - immunology
Lymphatic Metastasis
Medical sciences
Middle Aged
Prospective Studies
Radioimmunodetection
Radionuclide investigations
Technetium
Radionuclide study
Human
Carcinoma
Intravenous administration
Monoclonal antibody
Radioisotope
Scintigraphy
Malignant tumor
Globulin
Immunoradiodiagnosis
Carcinoembryonic antigen
Diagnosis
Mammary gland
Milk fat
ISSN:0735-7907, 1532-4192
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The current study attempted to assess the potential proficiency of radioimmunodetection (RAID) of primary, residual, multicentric, and recurrent breast carcinoma using two radiolabeled murine monoclonal antibodies (MoAbs), anti-human milk fat globulin (HMFG1) labeled with iodine (123I) and anti-carcinoembryonic antigen (CEA) labeled with technetium (99Tc). Thirteen patients with suspicious clinical andlor mammographic primary or recurrent breast carcinoma were studied in a phase I-II prospective, consecutive, nonrandomized, noncontrolled study. Five patients received intravenous infusion with 0.5-2.0 mg anti-CEA MoAb type CYT 380 labeled with 99Tc [13-22 millicurie (mCI)] and 8 patients received intravenous infusion with 0.25-1.0 mg anti-HMFG1 MoAb (Unipath, U.K.) labeled with 123 I (4-17mCI). Both MoAbs used in this study demonstrated ability to bind specifically to breast cancer lesions, resulting in successful RAID in 10 of 12 of studied patients (5 of 5 patients in the anti-CEA-99Tc and 5 of 7 in the anti-HMFG-123I group-accuracy 83.3%). One patient was excluded due to protocol violation. Seven patients had true-positive scans when correlated with surgery (sensitiviv 87.5%) The MoAb scans accurately diagnosed lesions in 3 of the 4 primary invasive breast carcinomas confirmed histologically. Presence of residual carcinoma following wide excision was established in 1 of 2 patients and presence of soft tissue metastases in 3 patients. Three patients had true-negutive scan (specificity 75%): 2 patients presented with suspicious mammographic recurrence postlumpectomy and 1 patient had questionable soft tissue recurrence. One patient with primary breast carcinoma had a false-negative scan and another had a false-positive scan in the presence of fibrosis following lumpectomy and radiation therapy. No adverse reactions were noted in the patients studied. RAID findings were confirmed by immuno-histochemistry in 6 of 9 cases studied. Our data suggest that radiolabeled MoAbs used in this study are potentially useful diagnostic agents for evaluation of primary or recurrent breast carcinoma, particularly in the areas where conventional methodology is limited.
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0735-7907
1532-4192
DOI:10.3109/07357909509024925